Royal Pharmaceuticals Industries Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 08-11-2024
- Paid Up Capital ₹ 0.10 M
as on 08-11-2024
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.00 Cr
as on 08-11-2024
- Revenue %
(FY 2023)
- Profit -111.85%
(FY 2023)
- Ebitda -21.81%
(FY 2023)
- Net Worth -264.55%
(FY 2023)
- Total Assets 90.59%
(FY 2023)
About Royal Pharmaceuticals Industries
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹20.00 Cr.
Nilesh Mehta and Sevantilal Champaneri serve as directors at the Company.
- CIN/LLPIN
U24100MH2022PTC375814
- Company No.
375814
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Feb 2022
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Royal Pharmaceuticals Industries?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Mehta  | Director | 01-Feb-2022 | Current |
| Sevantilal Champaneri | Director | 01-Feb-2022 | Current |
Financial Performance and Corporate Structure Insights of Royal Pharmaceuticals Industries.
Royal Pharmaceuticals Industries Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 111.85% decrease in profit. The company's net worth observed a substantial decline by a decrease of 264.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Royal Pharmaceuticals Industries?
In 2023, Royal Pharmaceuticals Industries had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Prudent Natural Products Private LimitedActive 22 years 3 months
Nilesh Mehta and Sevantilal Champaneri are mutual person
- Royal Pharma Private LimitedInactive For E-Filing 7 months
Nilesh Mehta and Sevantilal Champaneri are mutual person
- Legaltors Realiinfra Private LimitedActive 5 years 8 months
Sevantilal Champaneri is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 05 Jan 2024 | ₹20.00 Cr | Open |
How Many Employees Work at Royal Pharmaceuticals Industries?
Unlock and access historical data on people associated with Royal Pharmaceuticals Industries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Royal Pharmaceuticals Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Royal Pharmaceuticals Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
